Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
Cancer Discovery
|
January 7, 2016
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen, Youyan Zhang, Robert D Van Horn, et al.
Journal for Immunotherapy of Cancer
|
June 6, 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Rikke B Holmgaard, David A Schaer, Yanxia Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2017
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> Mutations
Yung-Mae M Yao, Gregory P Donoho, Philip W Iversen, et al.
Nature Biotechnology
|
May 25, 2010
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh, Anthony Lima, Rafael Molina, et al.
Genetics
|
March 4, 2005
Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene
Kyle A Edgar, Marcia Belvin, Annette L Parks, et al.
Molecular Cancer Therapeutics
|
April 4, 2020
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Helen Kotanides, Rose Marie Sattler, Maria B Lebron, et al.
Nature Communications
|
September 10, 2022
Therapeutic high affinity T cell receptor targeting a KRAS<sup>G12D</sup> cancer neoantigen
Andrew Poole, Vijaykumar Karuppiah, Annabelle Hartt, et al.
Molecular Cancer Therapeutics
|
November 21, 2019
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Shripad V Bhagwat, William T McMillen, Shufen Cai, et al.
Cancer Immunology Research
|
September 3, 2020
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Helen Kotanides, Yiwen Li, Maria Malabunga, et al.
Cancer Cell
|
September 8, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng, James R Henry, Michael D Kaufman, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
Cancer Discovery
|
January 7, 2016
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen, Youyan Zhang, Robert D Van Horn, et al.
Journal for Immunotherapy of Cancer
|
June 6, 2018
Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade
Rikke B Holmgaard, David A Schaer, Yanxia Li, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 15, 2017
Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <i>BRAF</i> or <i>KRAS</i> Mutations
Yung-Mae M Yao, Gregory P Donoho, Philip W Iversen, et al.
Nature Biotechnology
|
May 25, 2010
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Mallika Singh, Anthony Lima, Rafael Molina, et al.
Genetics
|
March 4, 2005
Synthetic lethality of retinoblastoma mutant cells in the Drosophila eye by mutation of a novel peptidyl prolyl isomerase gene
Kyle A Edgar, Marcia Belvin, Annette L Parks, et al.
Molecular Cancer Therapeutics
|
April 4, 2020
Characterization of 7A5: A Human CD137 (4-1BB) Receptor Binding Monoclonal Antibody with Differential Agonist Properties That Promotes Antitumor Immunity
Helen Kotanides, Rose Marie Sattler, Maria B Lebron, et al.
Nature Communications
|
September 10, 2022
Therapeutic high affinity T cell receptor targeting a KRAS<sup>G12D</sup> cancer neoantigen
Andrew Poole, Vijaykumar Karuppiah, Annabelle Hartt, et al.
Molecular Cancer Therapeutics
|
November 21, 2019
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine
Shripad V Bhagwat, William T McMillen, Shufen Cai, et al.
Cancer Immunology Research
|
September 3, 2020
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Helen Kotanides, Yiwen Li, Maria Malabunga, et al.
Cancer Cell
|
September 8, 2015
Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng, James R Henry, Michael D Kaufman, et al.
Page
of 10